RxDoctor Payments Data

Ahmed Shim, MD

Clinical Cardiac Electrophysiology · Indianapolis, INNPI 1609273085

Payments from drug & device makers

What this record shows

This record is dominated by grants: $31,212 of the $42,810 with a category attached, or 72.9%. 16 manufacturers reported payments, led by Medtronic at 53.4% of the total. Reporting peaked in 2020 at $18,073 and has fallen 96.8% since, to $586 in 2025.

$42,810in general payments, 2019–2025

Across 124 payments — averaging $345.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$23K
  • Boston Scientific$13K
  • Abbott$5K
  • Biosense Webster, Inc.$830
  • Biotronik Inc.$134
  • Altathera Pharmaceuticals LLC$119
  • plus $342 from 10 others

What the payments were for

  • Grants$31,21273%
  • Travel & lodging$5,55713%
  • Food & beverage$5,85714%
  • Education$1840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,810 in reported general payments places this provider in the 70th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

See all clinical cardiac electrophysiology providers in Indiana

Medicare billing

Part B allowed, 2024
$83,469
Medicare patients
721
Services billed
1,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban140$125,917
EntrestoSacubitril/Valsartan29$25,518
XareltoRivaroxaban22$19,480
FarxigaDapagliflozin Propanediol17$14,205
Flecainide Acetate61$1,941
Midodrine Hcl27$1,413
Metoprolol Succinate133$1,131
Diltiazem 24hr Er (Cd)Diltiazem Hcl35$680
Amiodarone Hcl55$480
Atorvastatin Calcium23$181
Carvedilol24$161
Losartan Potassium13$94
Lisinopril12$49
Rosuvastatin Calcium15$44
Omeprazole13$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$125,917140 claims
NovartisEntresto$23$25,51829 claims
Johnson & JohnsonXarelto$21$19,48022 claims
AstraZenecaFarxiga$46$14,20517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

Other clinical cardiac electrophysiology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →